Daito Pharmaceutical Co.,Ltd.
Notice Regarding Share Buyback and Share Buyback Through off-auction ToSTNeT-3
As part of the medium-term management plan's capital policy, a share buyback will be conducted. The plan is to acquire 500,000 ordinary shares (upper limit) with a total upper limit of 625,000,000 yen, with the ToSTNeT-3 buy order scheduled for 2026-07-13 at 08:45 JST, and the results of the buyback will be announced on the same day. As of now, the outstanding shares are 28,838,162, with 16,718 treasury shares (excluding specific trust assets).
Key Figures
- Total number of shares to be acquired: 500,000 shares
- Total value of purchases: 625,000,000 yen
- Shareholdings of treasury shares (as of 2026/06/30): 16,718 shares
AI要約
Overview of Capital Policy
In today's disclosed board resolution, we will acquire treasury shares and purchase them via ToSTNeT-3 in accordance with the Articles of Incorporation. The purpose of the acquisition is to return value to shareholders and improve capital efficiency in line with the medium-term management plan. The acquisition comprises up to 500,000 ordinary shares, with a total upper limit of 625,000,000 yen. The schedule is a limited buy order until 08:45 on July 13, 2026. Results of the acquisition will be announced after 08:45 on the same day.
Outlook and Impact
This share buyback is being conducted as part of the capital policy to reinforce shareholder returns and mitigate dilution, aiming to enhance shareholder value. It is noted that based on market conditions, some or all of the purchases may not be executed, and the publication of results will depend on whether the plan proceeds as scheduled. Currently, the treasury share ratio to total issued shares is about 0.058% (calculated from disclosed figures), and the impact on shareholder value is expected to be limited due to the upper-limit setting.
Daito Co., Ltd.
Company overview · Stock price · Financial data · All IR
